ClinicalTrials.gg
Not yet recruitingNCT07225699Updated Jul 13, 2026

IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING

An interventional study of Oasis 72-Hour collagen shield and sham collagen shield in Corneal Abrasions, sponsored by Milton S. Hershey Medical Center. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-center, double-arm, patient masked, randomized controlled trial. Subjects will be enrolled in the Emergency Department at the Penn State Milton S. Hershey Medical Center. Eligible subjects must present to the ED and be diagnosed with a traumatic corneal abrasion. One eye from each patient will be considered the study eye.

02

Conditions studied

  • Corneal Abrasions

Browse trials for

03

In context

Corneal Injuries

38 studies on the registry are indexed under Corneal Injuries; 8 are open to participants now.

This study's planned enrollment of 60 is above the median of 36 across 28 interventional studies indexed under Corneal Injuries.

Browse Corneal Injuries studies →

Lead sponsor

Milton S. Hershey Medical Center is the lead sponsor of 493 studies on the registry; 60 are open to participants now.

Of its 58 completed or terminated interventional studies of FDA-regulated products, 46 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each of the following criteria must be met for study participation:

    1. Male or female, age 18 or older at the time of study enrollment.
    2. Corneal abrasion in one eye.
    3. Willingness to sign the IRB-approved form (ICF) for study participation.
    4. Availability, willingness, and sufficient cognitive awareness to return for study-required visits and comply with examination procedures.

Exclusion criteria

Exclusion Criteria:

Patient candidates presenting any of the following characteristics will not be eligible for study participation:

<!-- -->

  1. Corneal abrasion in both eyes.
  2. Allergy to moxifloxacin or other fluoroquinolone antibiotics.
  3. Allergy to ibuprofen or other non-steroidal anti-inflammatory drugs.
  4. History of neurotrophic cornea for any reason, in the study eye.
  5. History of medical conditions known to cause decreased corneal sensation in the study eye including but not limited to HSV, HZO, and diabetes.
  6. History of extraocular surgical procedures known to cause decreased corneal sensation in the study eye, including but not limited to trigeminal nerve clamp.
  7. Any anterior segment pathology in the study eye that could significantly affect corneal wound healing (e.g. aniridia, corneal dystrophies [ABMD], etc.)
  8. Any visually significant intraocular media opacity other than corneal abrasion in the study eye (as determined by the investigator). Such opacities might include corneal scar or vitreous hemorrhage.
  9. History of any clinically significant retinal pathology or ocular diagnosis in the study eye that could, in the investigator's best judgement, alter or limit visual acuity (e.g. ischemic disease, macular degeneration, retinal detachment, optic neuropathy, amblyopia, strabismus, aniridia, epiretinal membrane, etc.).
  10. History of uveitis in either eye.
  11. History of intraocular or corneal surgery in the study eye besides laser peripheral iridotomy (LPI), retinal barrier laser.
  12. Current ocular infection in the study eye.
  13. Presence of uncontrolled systemic disease that could limit capacity to sign consent or comply with treatment schedule (e.g. mental illness, dementia, etc.).
  14. Unsuitable for study participation for any other reason, as determined by the Investigator's clinical judgement
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment group (Oasis 72-Hour Collagen Shield)

    The treatment group will receive an Oasis 72-Hour collagen shield and instructions to take moxifloxacin 0.5% four times daily as well as ibuprofen 400 mg PO q4 hrs as needed for pain.

    Device: Oasis 72-Hour collagen shield

  • Active comparator
    Control Group ( Sham Collagen Shield )

    The control group will have a sham collagen shield placed (patient will have the impression a lens is placed but it will not actually remain on the eye), and will also be prescribed moxifloxacin 0.5% four times daily and ibuprofen 400 mg PO q4 hrs as needed for pain.

    Device: sham collagen shield

Interventions

  • DeviceOasis 72-Hour collagen shield

    All qualified subjects will receive a drop of tetracaine. The treatment group will receive an Oasis 72-Hour collagen shield and instructions to take moxifloxacin 0.5% four times daily as well as ibuprofen 400 mg PO q4 hrs as needed for pain.

  • Devicesham collagen shield

    The control group will have a sham collagen shield placed (patient will have the impression a lens is placed but it will not actually remain on the eye), and will also be prescribed moxifloxacin 0.5% four times daily and ibuprofen 400 mg PO q4 hrs as needed for pain

06

What researchers measure

Primary outcomes

  1. Pain Score 4 hours

    \- The primary endpoint will be pain score (10-point Liekert scale) 0=No pain 10=more pain

    Time frame: four hours after leaving the emergency department.

  2. Pain score 24 hours

    The Secondary endpoint will be pain score (10-point Liekert scale) score 0=No pain 10=more pain

    Time frame: 24 hours after discharge from the emergency department

  3. Pain Score 72 hours

    The Secondary endpoint will be pain score (10-point Liekert scale) score 0=No pain 10=more pain

    Time frame: 72 hours after discharge from the emergency department

Secondary outcomes

  1. Dosage NSAID use in first 24 hours

    Dosage of non-steroidal anti-inflammatory drugs (NSAIDs)

    Time frame: in the first 24 hours after being discharged from the emergency department

  2. Frequency NSAID 24 Hour

    Time frame: 24 Hour

  3. Pain score 24 hours

    The Secondary endpoint will be pain score (10-point Liekert scale) score 0=No pain 10=more pain

    Time frame: 24 hours after discharge from the emergency department

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2029, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2025
First posted
Nov 10, 2025
StartEst.
Nov 15, 2026
Primary completionEst.
Jan 15, 2029
CompletionEst.
Jan 30, 2029
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225699
Responsible party
Murtaza Akhter (Physician Scientist, Milton S. Hershey Medical Center) — Principal investigator
First posted
Nov 10, 2025
Start date
Nov 15, 2026 (estimated)
Primary completion
Jan 15, 2029 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Jul 13, 2026

Study contacts

Uzma Muzammil, MBBS
Contact
umuzammil@pennstatehealth.psu.edu
717-531-0003 ext. 287070
Tealia Wiesman
Contact
twiesman@pennstatehealth.psu.edu
717-531-0003 ext. 287070
Murtaza Akhter, MD
principal investigator · Milton S. Hershey Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion